Today: 19 May 2026
Browse Category

NASDAQ:SLS 18 October 2025 - 13 May 2026

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Life Sciences said its pivotal REGAL leukemia trial has recorded 78 of 80 events needed for final analysis, triggering a rise in after-hours trading. The company reported a first-quarter net loss of $8.4 million but ended March with $107.1 million in cash. Research and development spending increased to $5.1 million. SELLAS expects its cash to fund operations for at least 12 months.
13 May 2026
···
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.
23 December 2025
·
SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (NASDAQ: SLS) traded at $1.74 per share as of 09:13 UTC on December 8, 2025, following new Phase 2 data for its SLS009 drug in relapsed/refractory AML-MR. The study showed a 46% overall response rate in 35 patients, with no dose-limiting toxicities or treatment-related deaths reported. The company plans to expand trials to newly diagnosed high-risk AML in early 2026.
8 December 2025
··
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences shares closed at $2.14 on Oct. 17, up about 100% year-to-date, then surged another 38% after hours. BlackRock disclosed a 5.4% stake on Oct. 18, joining other major funds that increased holdings in Q2. Sellas’s lead AML drug passed a Phase 3 interim safety review, and its CDK9 inhibitor showed promising Phase 2 results. The company ended Q2 with $25 million cash and raised $23.6 million in September.
20 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

SELLAS Life Sciences (NASDAQ: SLS) shares doubled year-to-date in 2025, closing at $2.14 on Oct. 17 after a 38% after-hours jump and hitting a 52-week high of $2.27. BlackRock disclosed a 5.4% stake in the company. Interim Phase 3 trial results for SELLAS’s lead cancer drug showed median survival over 13.5 months in AML patients. Final trial data is expected by year-end 2025.
18 October 2025

Stock Market Today

  • Polymarket Teams Up with Nasdaq Private Market to Settle Pre-IPO Event Contracts
    May 19, 2026, 1:43 PM EDT. Prediction market platform Polymarket has partnered with Nasdaq Private Market to enhance settlement of event contracts related to privately held companies, including IPO timing and valuation milestones. Nasdaq Private Market, a key provider of private market liquidity and investment infrastructure, will act as the resolution data source for these contracts. The collaboration launches new private company prediction markets on Polymarket, expanding beyond previous models relying solely on public information. This move targets a massive private market with nearly 1,600 unicorns valued at over $5 trillion, aiming to broaden access beyond institutional and high-net-worth investors. The partnership introduces more transparent and verifiable private company event markets prior to IPOs, democratizing private market engagement.

Latest articles

Wall Street’s Top Picks for U.S. Stocks as Yields Stay High

Wall Street’s Top Picks for U.S. Stocks as Yields Stay High

19 May 2026
U.S. stocks fell Tuesday as the 10-year Treasury yield reached its highest point since January 2025, pressuring growth shares. Nvidia drew the most attention ahead of its earnings, with options markets pricing in a possible $355 billion swing in value. Dell highlighted new AI infrastructure partnerships, while ServiceNow received a fresh Buy rating from Bank of America.
Nvidia’s Earnings Could Make or Break the AI Stock Trade

Nvidia’s Earnings Could Make or Break the AI Stock Trade

19 May 2026
Nvidia rose 0.8% ahead of its earnings report, while CoreWeave dropped 3.7% after Google and Blackstone announced a $5 billion U.S. AI cloud venture using Google’s custom TPUs. The new venture will offer 500 megawatts of data-center capacity by 2027. AMD and Micron also gained, but Microsoft and Broadcom slipped. Investors are watching whether Nvidia can maintain dominance as competition in AI inference intensifies.
Uranium Energy Shares Fall Close to 10% as Nuclear-Fuel Plays Get Hit

Uranium Energy Shares Fall Close to 10% as Nuclear-Fuel Plays Get Hit

19 May 2026
Uranium Energy Corp. shares dropped 9.6% to $11.93 in midday New York trading Tuesday, outpacing declines in other uranium stocks and the Global X Uranium ETF. UEC reported a $13.9 million net loss on $20.2 million in sales for its latest quarter, with 45,743 pounds of uranium concentrate produced at $44.14 per pound.
Go toTop